Arizona State University researchers developed a urine-based diagnostic screening tool designed to identify autism spectrum disorder (ASD) biochemical signatures in children as young as two years old. The approach is positioned as an early, non-invasive screening option that could accelerate referral and intervention compared with later behavioral assessments. The work centers on detecting biochemical patterns in urine linked to ASD, aiming to provide an objective indicator that complements clinical evaluation. Early detection is particularly impactful because early behavioral and therapeutic support can materially influence developmental trajectories. For biotech and diagnostics stakeholders, the key near-term questions will be analytical validation, sensitivity/specificity across subgroups, and clinical validation in prospective cohorts. Regulatory pathway and reimbursement feasibility will likely hinge on performance benchmarks and the feasibility of scaling the assay in routine clinical labs.